Sales Of Biologics was Adia Med’s largest product and service line in fiscal 2025, bringing in $443.75K of $700.51K (63%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Sales Of Biologics | — | $443.75K |
| Medical Procedures | — | $245.60K |
| Sales Of Prducts & Services | $6.38K | — |
| Shipping & Delivery | — | $5.14K |
| Sales Of Supplements | — | $3.39K |
| Services | — | $2.27K |
| Sales Of Ancillary Products | — | $360 |
| Total | $6.38K | $700.51K |
Adia Med brought in $700.51K from its six product and service lines in fiscal 2025, the year ended December 31, 2025. Adia Med regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $6.38K. Sales Of Biologics was the largest at $443.75K (63.3%), ahead of Medical Procedures at $245.60K (35.1%) and Shipping & Delivery at $5.14K (0.7%). The other three lines brought in $6.02K combined.
Adia Med began breaking out Sales Of Biologics in fiscal 2025, Medical Procedures in fiscal 2025, Shipping & Delivery in fiscal 2025 and Sales Of Supplements in fiscal 2025. Adia Med stopped reporting Sales Of Prducts & Services as a separate line after fiscal 2024, when it brought in $6.38K.
Adia Labs was Adia Med’s largest segment in fiscal 2025, bringing in $448.89K of $700.51K (64%).
| Segment | FY 2024 | FY 2025 |
|---|---|---|
| Adia Labs | — | $448.89K |
| Adia Med | — | $245.96K |
| Biolete | $6.38K | $3.39K |
| Corporate | — | $2.27K |
| Total | $6.38K | $700.51K |
Adia Med brought in $700.51K from its four segments in fiscal 2025, the year ended December 31, 2025. Adia Med regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $6.38K. Adia Labs was the largest at $448.89K (64.1%), ahead of Adia Med at $245.96K (35.1%) and Biolete at $3.39K (0.5%). The remaining segment, Corporate, brought in $2.27K.
Adia Med began breaking out Adia Labs in fiscal 2025, Adia Med in fiscal 2025 and Corporate in fiscal 2025.
Adia Med (ADIA) reports its revenue by product and service and by segment. In fiscal 2025, Sales Of Biologics was its largest product and service line, bringing in $443.75K (63.3% of the total), followed by Medical Procedures at $245.60K (35.1%).
Sales Of Biologics was Adia Med's largest product and service line in fiscal 2025, bringing in $443.75K, or 63.3% of the $700.51K total across its six product and service lines.
Adia Labs was Adia Med's largest segment in fiscal 2025, bringing in $448.89K, or 64.1% of the $700.51K total across its four segments.
Every figure comes from Adia Med's annual financial filings, as reported. Each line keeps the name Adia Med gives it, and years follow its fiscal calendar.
Adia Med's revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.